Visaria Aayush, McDonald William, Mancini John, Ambrosy Andrew P, Kwak Min Ji, Hashemi Ashkan, Lachs Mark S, Zullo Andrew R, Safford Monika, Levitan Emily B, Goyal Parag
Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Drugs Aging. 2025 Jan;42(1):69-80. doi: 10.1007/s40266-024-01166-1. Epub 2024 Dec 27.
Medication regimen complexity may be an important risk factor for adverse outcomes in older adults with heart failure. However, increasing complexity is often necessary when prescribing guideline-directed medical therapy at the time of a heart failure hospitalization. We sought to determine whether increased medication regimen complexity following a heart failure hospitalization was associated with worse post-hospitalization outcomes.
This retrospective cohort study included Reasons for Geographic and Racial Differences in Stroke (REGARDS) participants aged at least 65 years hospitalized for heart failure between 2003 and 2014. We calculated changes between hospital admission and discharge in medication count (Δcount) and in the validated Medication Regimen Complexity Index (ΔMRCI), which incorporates each medication's dosage formulation, frequency, timing, and special instructions. The primary outcome was a composite of 90-day all-cause readmission and all-cause mortality post-discharge. We calculated ΔMRCI and Δcount, identified their predictors, and examined their association with the primary outcome.
Among 725 patients hospitalized for heart failure, the mean (SD) age was 77 (7.2) years, 46% were female, and 35% were Black. At discharge, nearly 75% had an increase in their medication regimen complexity and 60% had an increase in their medication count. Patients with the highest ΔMRCI and Δcount were more likely to be female and Black. Predictors of the highest ΔMRCI included Charlson comorbidity index and not being discharged home; predictors of the highest Δcount included intensive care unit stay. Approximately 48% of patients experienced a 90-day readmission or death. Neither ΔMRCI (highest versus lowest tertile; HR 1.14, 95% CI 0.86, 1.50) nor Δcount (HR 0.97, 95% CI 0.73, 1.27) were associated with 90-day outcomes.
Following a heart failure hospitalization, increased medication regimen complexity was common but was not associated with 90-day post-hospitalization outcomes. These are reassuring data, suggesting that it is reasonable for clinicians to focus on optimizing medication regimens for patients with heart failure even if it increases regimen complexity.
药物治疗方案的复杂性可能是老年心力衰竭患者不良结局的一个重要危险因素。然而,在心力衰竭住院时开具指南指导的药物治疗时,增加治疗方案的复杂性往往是必要的。我们试图确定心力衰竭住院后药物治疗方案复杂性增加是否与出院后更差的结局相关。
这项回顾性队列研究纳入了2003年至2014年间因心力衰竭住院的年龄至少65岁的《卒中地理和种族差异原因》(REGARDS)参与者。我们计算了入院和出院之间药物数量的变化(Δ计数)以及经过验证的药物治疗方案复杂性指数的变化(ΔMRCI),该指数纳入了每种药物的剂型、频率、用药时间和特殊说明。主要结局是出院后90天全因再入院和全因死亡率的综合指标。我们计算了ΔMRCI和Δ计数,确定了它们的预测因素,并研究了它们与主要结局的关联。
在725例因心力衰竭住院的患者中,平均(标准差)年龄为77(7.2)岁,46%为女性,35%为黑人。出院时,近75%的患者药物治疗方案复杂性增加,60%的患者药物数量增加。ΔMRCI和Δ计数最高的患者更可能为女性和黑人。ΔMRCI最高的预测因素包括Charlson合并症指数和未出院回家;Δ计数最高的预测因素包括入住重症监护病房。约48%的患者经历了90天再入院或死亡。ΔMRCI(最高三分位数与最低三分位数相比;风险比1.14,95%置信区间0.86,1.50)和Δ计数(风险比0.97,95%置信区间0.73,1.27)均与90天结局无关。
心力衰竭住院后,药物治疗方案复杂性增加很常见,但与出院后90天结局无关。这些数据令人安心,表明即使增加治疗方案复杂性,临床医生专注于优化心力衰竭患者的药物治疗方案也是合理的。